Salta al contenuto principale
Passa alla visualizzazione normale.

MATILDE TODARO

Magnetic Nanoparticle-Based Hyperthermia Mediates Drug Delivery and Impairs the Tumorigenic Capacity of Quiescent Colorectal Cancer Stem Cells

  • Autori: Fernandes, Soraia; Fernandez, Tamara; Metze, Sabrina; Balakrishnan, Preethi B; Mai, Binh T; Conteh, John; De Mei, Claudia; Turdo, Alice; Di Franco, Simone; Stassi, Giorgio; Todaro, Matilde; Pellegrino, Teresa
  • Anno di pubblicazione: 2021
  • Tipologia: Articolo in rivista
  • Parole Chiave: cancer stem cells; colorectal cancer; doxorubicin; magnetic hyperthermia; magnetic nanoparticles
  • OA Link: http://hdl.handle.net/10447/506874

Abstract

Cancer stem cells (CSCs) are the tumor cell subpopulation responsible for resistance to chemotherapy, tumor recurrence, and metastasis. An efficient therapy must act on low proliferating quiescent-CSCs (q-CSCs). We here investigate the effect of magnetic hyperthermia (MHT) in combination with local chemotherapy as a dual therapy to inhibit patient-derived colorectal qCR-CSCs. We apply iron oxide nanocubes as MHT heat mediators, coated with a thermoresponsive polymer (TR-Cubes) and loaded with DOXO (TR-DOXO) as a chemotherapeutic agent. The thermoresponsive polymer releases DOXO only at a temperature above 44 °C. In colony-forming assays, the cells exposed to TR-Cubes with MHT reveal that qCR-CSCs struggle to survive the heat damage and, with a due delay, restart the division of dormant cells. The eradication of qCR-CSCs with a complete stop of the colony formation was achieved only with TR-DOXO when exposed to MHT. The in vivo tumor formation study confirms the combined effects of MHT with heat-mediated drug release: only the group of animals that received the CR-CSCs pretreated, in vitro, with TR-DOXO and MHT lacked the formation of tumor even after several months. For DOXO-resistant CR-CSCs cells, the same results were shown, in vitro, when choosing the drug oxaliplatin rather than DOXO and applying MHT. These findings emphasize the potential of our nanoplatforms as an effective patient-personalized cancer treatment against qCR-CSCs.